CAMBRIDGE, UK, Sept. 3, 2001 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN.L) today announced the appointment of Mr. Dan Welch to the Board as a non-executive director.
Dan Welch, currently President of Elan Pharmaceuticals, joined the company in October 2000 and is responsible for all activities including Research and Development, as well as the pharmaceutical businesses throughout the world. Before joining Elan, Mr. Welch spent over 22 years in the pharmaceutical industry in the USA, Canada and Europe, including working for companies such as Adria Laboratories (now part of Pharmacia), American Hospital Supply (now Baxter), Sterling Drug, seven years with Sanofi-Synthelabo, and is now based in Dublin.
During these 22 years, Mr. Welch has held positions of increasing responsibility within major pharmaceutical companies. His areas of experience are sales and marketing, business development, international marketing and general management. Among his most recent notable accomplishments is the major role he played as one of the principal architects of Sanofi-Synthelabo's transformation from a $2 billion per year European-focused company to a $6 billion company recognized as a scientific leader and worldwide commercial player. Mr. Welch has had extensive experience in managing strategic partnerships having designed and/or led partnerships with BMS, Organon, Eli Lilly and Pharmacia. Mr. Welch graduated with honors from the University of Miami with a BBA degree in Marketing and holds an MBA, with a focus on finance, from the University of North Carolina.
"We welcome Dan's considerable and broad-ranging management expertise to our board and look forward to his active role in helping us deliver value for our shareholders," said Daniel Roach, Chief Executive Officer of CeNeS Pharmaceuticals plc.
Mr. Welch commented, "I am delighted to have the opportunity to join the board of CeNeS Pharmaceuticals, a young and highly promising company occupying a unique position in the pharmaceutical and biotechnology industry. I look forward to contributing to its future success."
CeNeS is a biopharmaceutical company specializing in the development and commercialization of drugs for CNS disorders and pain control. The company currently markets three products, and has a research and development pipeline targeting pain, stroke, schizophrenia, addiction, sleep disorders, Parkinson's disease and multiple sclerosis. CeNeS also has a cognitive division, which markets CANTAB, a computerized cognitive test, and a drug delivery division. In addition it has a range of platform technologies including AutoPatch(TM) its unique automated patch clamping technology. The group has around 130 staff working from modern research and manufacturing facilities in Cambridge, England, Irvine, Scotland and Boston, USA.
Please click on the link below to view the entire press release: http://reports.huginonline.com/833154/94129.pdf
Please contact Noonan/Russo on +44 (0)20 7726 4452 for further information.